Cargando…

A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease

PURPOSE: This study aimed to evaluate the therapeutic value of adalimumab (ADA) for fistula in Crohn's disease (CD). METHODS: A computerized search of electronic databases, including PubMed, Web of Science, Embase, Google scholar, and the Cochrane Library from 2000 to October 2016, was performe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Yin-mei, Chen, Ming, Liao, Ai-jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674503/ https://www.ncbi.nlm.nih.gov/pubmed/29204155 http://dx.doi.org/10.1155/2017/1745692

Ejemplares similares

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
por: Zeisler, Bella, et al.
Publicado: (2015)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn’s disease: a systematic review and meta-analysis
por: Gangwani, Manesh Kumar, et al.
Publicado: (2023)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
por: Ji, Cheng-Chun, et al.
Publicado: (2017)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
por: Xu, Lankai Cathy, et al.
Publicado: (2023)

MRI of perianal fistulas in Crohn’s disease
por: Reginelli, Alfonso, et al.
Publicado: (2020)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
por: Abdelqader, Abdelhai, et al.
Publicado: (2016)

Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
por: Atsawarungruangkit, Amporn, et al.
Publicado: (2017)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
por: Chen, Liang, et al.
Publicado: (2022)

Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study
por: Sirmai, Laura, et al.
Publicado: (2022)

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
por: Liu, Yifei, et al.
Publicado: (2022)

Adalimumab treatment in Crohn’s disease: an overview of long-term efficacy and safety in light of the EXTEND trial
por: Asgharpour, Amon, et al.
Publicado: (2013)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Reversible proteinuria after adalimumab discontinuation in a patient with Crohn's disease
por: Katsanos, Konstantinos H., et al.
Publicado: (2010)

Anti–NMDAR encephalitis in a patient with Crohn disease receiving adalimumab
por: Noble, Geoffrey P., et al.
Publicado: (2018)

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease
por: Faubion, William A., et al.
Publicado: (2017)

Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review
por: Cao, Yantian, et al.
Publicado: (2021)

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies
por: Panaccione, Remo, et al.
Publicado: (2019)

Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab
por: Vadala di Prampero, Salvatore, et al.
Publicado: (2016)

CNS TB-IRIS Following Cessation of Adalimumab in an Adolescent With Crohn’s Disease
por: Christian, Elizabeth, et al.
Publicado: (2022)

Current management of anal fistulas in Crohn's disease
por: Hermann, Jacek, et al.
Publicado: (2015)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Crohn’s Disease-Associated and Cryptoglandular Fistulas: Differences and Similarities
por: Zhou, Zhou, et al.
Publicado: (2023)

Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Disease Responsive to Adalimumab and Prednisone
por: Hutto, Spencer K., et al.
Publicado: (2021)

Primary Cutaneous Nocardiosis in a Patient Taking Adalimumab Therapy for Crohn’s Disease
por: Desai, Madhav, et al.
Publicado: (2017)

Langerhans Cell Histiocytosis Caused by Adalimumab for Crohn’s Disease: A Case Report
por: KOCHI, Mariko, et al.
Publicado: (2023)

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease
por: Ogata, Haruhiko, et al.
Publicado: (2016)

Vitiligo during Treatment of Crohn's Disease with Adalimumab: Adverse Effect or Co-Occurrence?
por: Posada, Celia, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2lqpgon2b5h0qjvl6v5ssn1498